Literature DB >> 4339388

The central action of clonidine and its antagonism.

F Katic, H Lavery, R D Lowe.   

Abstract

1. We have examined the central actions of clonidine (2-(2-6-dichlorphenylamine)-2-imidazoline hydrochloride). It has been confirmed that when infused into the vertebral artery at 2 mug/min, it caused a decrease in blood pressure and a slight increase in heart rate. The same dose given intravenously or into the carotid artery had no effect.2. Intravertebral clonidine also greatly reduced the reflex response to carotid occlusion and the effects of an intravertebral infusion of angiotensin (1 ng/kg)/min.3. This central action of clonidine was antagonized by the adrenergic neurone blocking drug bethanidine (4-5 mg/kg intravenously) even after the cervical cord had been transected at C(4)-C(6) suggesting that bethanidine also has central actions.4. Other drugs which also antagonized the central effects of clonidine were guanethidine (4-5 mg/kg intravenously), bretylium (10 mg/kg intravenously) and phentolamine (0.2 mg/kg intravenously).5. It is suggested that there are central adrenergic neurones which inhibit cardiovascular autonomic reflexes and that the central autonomic effects of clonidine are due to stimulation of inhibitory adrenoceptors. The antagonism by adrenergic neurone blocking drugs of the effect of clonidine could therefore be due to blockade of these inhibitory pathways.6. The central action of clonidine could only be demonstrated when a high concentration was infused into the vertebral artery and could not be shown with oral doses of (20 mug/kg)/day for seven days. It is concluded that the hypotensive action of therapeutic doses is unlikely to be due to the central action of clonidine.

Entities:  

Mesh:

Substances:

Year:  1972        PMID: 4339388      PMCID: PMC1665976          DOI: 10.1111/j.1476-5381.1972.tb07315.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  11 in total

1.  Importance of central vasomotor effects in angiotensin-induced hypertension.

Authors:  G C Scroop; F Katic; M D Joy; R D Lowe
Journal:  Br Med J       Date:  1971-02-06

2.  The cardiovascular response to vertebral artery infusions of angiotensin in the dog.

Authors:  R D Lowe; G C Scroop
Journal:  Clin Sci       Date:  1969-12       Impact factor: 6.124

3.  Efferent pathways of the cardiovascular response to vertebral artery infusions of angiotensin in the dog.

Authors:  G C Scroop; R D Lowe
Journal:  Clin Sci       Date:  1969-12       Impact factor: 6.124

4.  Investigations into the mechanism of the hypotensive effect of 2-(2,6-dichlorphenylamino)-2-imidazoline-HCl.

Authors:  W Kobinger; A Walland
Journal:  Eur J Pharmacol       Date:  1967-12       Impact factor: 4.432

5.  Analysis of the cardiovascular effects of 2-(2,6-dichlorophenylamino)-2-imidazoline hydrochloride (Catapres).

Authors:  J W Constantine; W K McShane
Journal:  Eur J Pharmacol       Date:  1968-09       Impact factor: 4.432

6.  Effect of the hypotensive drug ST 155 (Catapres) on the heart and peripheral circulation.

Authors:  W G Nayler; J M Price; J B Swann; I McInnes; D Race; T E Lowe
Journal:  J Pharmacol Exp Ther       Date:  1968-11       Impact factor: 4.030

7.  Acute hypotensive action of 2-(2,6-dichlorophenylamino)-2-imidazoline hydrochloride (St 155) after infusion into the cat's vertebral artery.

Authors:  R W Sattler; P A van Zwieten
Journal:  Eur J Pharmacol       Date:  1967-10       Impact factor: 4.432

8.  [First observations on an antihypertensive effect of 2-(2,6-dichlorophenylamino)-2-imidazoline hydrochloride in man].

Authors:  D Michel; W Zimmermann; A Nassehi; P Seraphim
Journal:  Dtsch Med Wochenschr       Date:  1966-09-02       Impact factor: 0.628

9.  [Pharmacological effects of 2-(2,6-dichlorophenylamino)-2-imidazoline hydrochloride, a new, antihypertensive substance].

Authors:  W Hoefke; W Kobinger
Journal:  Arzneimittelforschung       Date:  1966-08

10.  [Clinical and clinical-experimental studies with a new blood pressure lowering substance: dichlorophenylaminoimidazoline].

Authors:  K D Bock; V Heimsoth; P Merguet; J Schönermark
Journal:  Dtsch Med Wochenschr       Date:  1966-10-07       Impact factor: 0.628

View more
  5 in total

1.  Effect of clonidine on the excitability of vasomotor loci in the cat.

Authors:  B N Dhawan; M B Johri; G B Singh; R C Srimal; D Viswesaram
Journal:  Br J Pharmacol       Date:  1975-05       Impact factor: 8.739

2.  Localization of the central cardiovascular action of clonidine.

Authors:  P Bousquet; P G Guertzenstein
Journal:  Br J Pharmacol       Date:  1973-12       Impact factor: 8.739

Review 3.  Are the pharmacology and physiology of α₂ adrenoceptors determined by α₂-heteroreceptors and autoreceptors respectively?

Authors:  Ralf Gilsbach; Lutz Hein
Journal:  Br J Pharmacol       Date:  2012-01       Impact factor: 8.739

4.  Effects of the alpha 2-adrenergic agonist clonidine and its antagonist idazoxan on the fetal lamb.

Authors:  O S Bamford; G S Dawes; R Denny; R A Ward
Journal:  J Physiol       Date:  1986-12       Impact factor: 5.182

5.  Variants of ADRA2A are associated with fasting glucose, blood pressure, body mass index and type 2 diabetes risk: meta-analysis of four prospective studies.

Authors:  P J Talmud; J A Cooper; T Gaunt; M V Holmes; S Shah; J Palmen; F Drenos; T Shah; M Kumari; M Kivimaki; J Whittaker; D A Lawlor; I N Day; A D Hingorani; J P Casas; S E Humphries
Journal:  Diabetologia       Date:  2011-04-01       Impact factor: 10.122

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.